HOXD-AS1 is a predictor of clinical progression and functions as an oncogenic lncRNAs in papillary thyroid cancer.
作者： Kai Xu , Ying Feng
DOI: 10.1002/JCB.27809
关键词: Biomarker (medicine) 、 Cell growth 、 Carcinogenesis 、 Cancer research 、 Papillary thyroid cancer 、 Antisense RNA 、 Stage (cooking) 、 Thyroid cancer 、 Long non-coding RNA 、 Medicine
摘要: Long noncoding RNA HOXD cluster antisense 1 (HOXD-AS1) has been found to play a crucial role in the tumorigenesis and progression of human cancer. However, HOXD-AS1 papillary thyroid cancer is still unknown. The purpose this study was investigate clinical value biological function results showed overexpressed tissues cell lines compared with matching nontumor tissue specimens normal line, respectively. High expression associated elderly people, advanced stage, large tumor size, present lymph node metastasis, distant metastasis. There no significant correlation between disease-free survival or overall cohort from TCGA database. vitro suggested reduced inhibited proliferation, migration, invasion, promoted cell-cycle arrest. In conclusion, biomarker for predicting
sci-hub.se 参考文章(23)
Prabha Sampath, Vladimir A Kuznetsov, Igor V Kurochkin, Aliaksandr A Yarmishyn, Arsen O Batagov, Jovina Z Tan, Gopinath M Sundaram, None, HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome. BMC Genomics. ,vol. 15, pp. 1- 14 ,(2014) , 10.1186/1471-2164-15-S9-S7
Wanqing Chen, Rongshou Zheng, Peter D. Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He, Cancer statistics in China, 2015 CA: A Cancer Journal for Clinicians. ,vol. 66, pp. 115- 132 ,(2016) , 10.3322/CAAC.21338
Jianfa Li, Chengle Zhuang, Yuchen Liu, Mingwei Chen, Yincong Chen, Zhicong Chen, Anbang He, Junhao Lin, Yonghao Zhan, Li Liu, Wen Xu, Guoping Zhao, Yinglu Guo, Hanwei Wu, Zhiming Cai, Weiren Huang, Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer Journal of Experimental & Clinical Cancer Research. ,vol. 35, pp. 99- 99 ,(2016) , 10.1186/S13046-016-0372-5
Marc Pusztaszeri, Manon Auger, Update on the cytologic features of papillary thyroid carcinoma variants Diagnostic Cytopathology. ,vol. 45, pp. 714- 730 ,(2017) , 10.1002/DC.23703
Omar A. Karadaghy, Dorina Kallogjeri, Jay F. Piccirillo, Development of a New Clinical Severity Staging System for Patients With Nonmetastatic Papillary Thyroid Carcinoma JAMA Otolaryngology–Head & Neck Surgery. ,vol. 143, pp. 1173- 1180 ,(2017) , 10.1001/JAMAOTO.2017.0550
Peng Gu, Xu Chen, Ruihui Xie, Jinli Han, Weibin Xie, Bo Wang, Wen Dong, Changhao Chen, Meihua Yang, Junyi Jiang, Ziyue Chen, Jian Huang, Tianxin Lin, None, lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Molecular Therapy. ,vol. 25, pp. 1959- 1973 ,(2017) , 10.1016/J.YMTHE.2017.04.016
Li Zheng, Jiangtao Chen, Zhongyong Zhou, Zhikuan He, Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway. Tumor Biology. ,vol. 39, pp. 1010428317705335- 1010428317705335 ,(2017) , 10.1177/1010428317705335
Yuri E. Nikiforov, ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW. Endocrine Practice. ,vol. 23, pp. 979- 988 ,(2017) , 10.4158/EP171805.RA
Benjamin R. Roman, Luc G. Morris, Louise Davies, The thyroid cancer epidemic, 2017 perspective. Current Opinion in Endocrinology, Diabetes and Obesity. ,vol. 24, pp. 332- 336 ,(2017) , 10.1097/MED.0000000000000359
Jian-kang Huang, Ling Ma, Wen-hua Song, Bang-yu Lu, Yu-bin Huang, Hui-ming Dong, Xiao-kai Ma, Zheng-zhi Zhu, Rui Zhou, LncRNA-MALAT1 Promotes Angiogenesis of Thyroid Cancer by Modulating Tumor-Associated Macrophage FGF2 Protein Secretion. Journal of Cellular Biochemistry. ,vol. 118, pp. 4821- 4830 ,(2017) , 10.1002/JCB.26153